Zylox-Tonbridge Details Board and Committee Structure in Governance Update

Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) has provided an announcement.

Zylox-Tonbridge Medical Technology Co., Ltd. has announced the current composition of its board of directors, listing three executive directors, two non-executive directors, and three independent non-executive directors, with Dr. Jonathon Zhong Zhao serving as chairman. The disclosure also details the structure of the audit, remuneration, and nomination committees, clarifying which directors serve as chairpersons or members, thereby enhancing governance transparency and providing investors with clearer visibility into the company’s oversight and decision-making framework.

By outlining the responsibilities across its three key board committees, the company signals an emphasis on balanced oversight in areas such as financial reporting, executive pay, and director nominations. This governance update may strengthen stakeholder confidence in the board’s independence and effectiveness, supporting Zylox-Tonbridge’s positioning as a well-governed medical technology player in the Hong Kong capital market.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H

Zylox-Tonbridge Medical Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 2190. Operating in the medical technology sector, the company focuses on developing and providing medical devices and related healthcare solutions for the broader Chinese and international markets.

Average Trading Volume: 741,252

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.65B

For a thorough assessment of 2190 stock, go to TipRanks’ Stock Analysis page.